| |
|
SHS Newsletter – To open this newsletter in your browser, please click here.
|
| |
|
|
|
| |
January 2018
|
 |
|
|
|
| |
| |
|
Dear Sir or Madam,
|
| |
Product launches, awards, workshops made the last few months of 2017 very eventful for us and our portfolio companies. Both the specialty pharmaceuticals company AMW and GNA Biosolutions have successfully introduced new products. We are also particularly pleased by the fact that EIT's entry into the US market was very successful. Many American surgeons are now already using the 3D-printed spinal implants.
We will be further expanding our network activities in the USA in 2018. Our long-time partner André Zimmermann has assumed responsibility for international business development and will be helping our portfolio companies gain a foothold in one of the world's most attractive medical technology markets.
I would also like to draw your attention to an upcoming event. Together with the medical technology industry initiative Medical Mountains, MBG Baden-Württemberg and SHS Gesellschaft für Beteiligungsmanagement have organized the event "Challenges and Financing Options for Medical Technology Companies" on February 27th, 2018 in Hausen ob Verena. The focus here will be on succession planning and funding opportunities for growing medical technology companies.
|
| |
|
| |
|
Hubertus Leonhardt
|
|
|
|
| |
| |
|
Topics
|
| |
| • |
SHS strengthens network activities in the USA - André Zimmermann assumes responsibility for international business development
|
| |
|
|
|
| • |
Investment campaign for Europe: EIB provides financing to AMW GmbH in Warngau
|
| |
|
|
| • |
GNA Biosolutions presents a new ultra-fast PCR platform at the Medica trade fair in Düsseldorf
|
| |
|
|
| • |
AOT presents its robot CARLO as part of Schweizer Digitaltag
|
| |
|
|
| • |
EIT also gains footing in the USA
|
| |
|
|
| • |
Tyromotion receives "Top of Styria" award
|
| |
|
|
| • |
Follow-up financing for Miracor Medical
|
| |
|
|
|
| • |
Event announcement: "Challenges and financing options for medical technology companies" on February 27th, 2018 in Tuttlingen Hausen ob Verena
|
| |
|
|
| • |
SHS at the Forum Medtech Pharma in Nuernberg
|
| |
|
|
| • |
SHS at the CatCap Venture Lounge in Darmstadt
|
| |
|
|
|
|
|
| • |
Jobs at portfolio companies
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
SHS strengthens network activities in the USA - André Zimmermann assumes responsibility for international business development |
|
|
| |
| |
.jpeg "AZ") |
| |
| Dr. André Zimmermann, Partner at SHS (Foto: schreier.co) |
|
|
|
SHS intends to intensify its networking activities and further tap into the attractive US healthcare market for its portfolio companies. As part of this effort, company partner André Zimmermann has assumed responsibility for international business development with a focus on the USA.
|
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
Investment campaign for Europe: EIB provides financing to AMW GmbH in Warngau |
|
|
| |
| |
.jpeg "AMW_EIB") |
| |
| From left to right: Yu Zhang (EIB), Anna Stodolkiewicz (EIB), Matthias Schott (FCF), Vytenis Andriukaitis (European Commissioner Healthcare), Marcel Lange (FCF), Petra Menter-Fischer (AMW), Dr. Wilfried Fischer (AMW), Ambroise Fayolle (EIB) and Philipp Karbach (AMW) |
|
|
|
The European Investment Bank (EIB) is provided 25 million euros to AMW GmbH (AMW). AMW is a specialty pharmaceuticals company focused on cutting-edge drug delivery systems. SHS invested in AMW in 2008 as one of its founding investors. With this new financing, AMW can intensify its development of innovative medicines, conduct clinical trials and expand production capacity at its plant in Warngau and at its subsidiary Endomedica in Halle. In addition to this, a new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company's headquarters in Warngau.
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2008
Business purpose: Development, production and marketing / out-licensing of specialty pharmaceuticals.
Products: Transdermal systems (drug patches) and active implants for medical applications in oncology, neurology, psychiatry and endocrinology.
Location: Warngau (D)
|
|
| |
|
|
|
|
|
| |
| |
|
|
| |
GNA Biosolutions presents a new ultra-fast PCR platform at the Medica trade fair in Düsseldorf |
|
|
| |
| |
The molecular technology company GNA Biosolutions presented its new product Pharos V8 at the Medica in Düsseldorf, one of the world's largest medical trade fairs. The ultra-fast PCR instrument is used for in-vitro research.
|
|
|
|
|
.jpeg "GNAs Pharos V8") |
| |
| GNA's Pharos V8 – the world's first laser PCR® platform |
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2010
Business purpose: Development, production and distribution of molecular diagnostic tests (POC/PON) and devices that are at least 10 times faster based on laser PCR technology to accelerate time-critical diagnoses (e.g. in case of infections) for the benefit of the patient.
Products: PharosV8
Location: Martinsried (D) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
AOT presents its robot CARLO as part of Schweizer Digitaltag |
|
|
| |
| |
.jpeg "AOT_Carlo") |
| |
| The inventor and his robot: Alfredo Bruno and the bone laser Carlo. |
|
|
|
The robotic surgery company AOT presented its robot CARLO as part of Schweizer Digitaltag. CARLO replaces outdated bone surgery methods using saws, milling machines or ultrasound with innovative bone laser technologies.
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2010
Business purpose: development, production and marketing of computer assisted laser systems for bone surgery
Products: CARLO (Cold Ablation Robot-guided Laser Osteotome) (surgery system
Locations: Basel (CH) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
EIT also gains footing in the USA |
|
|
| |
| |
With its innovative spinal implants, the German manufacturer of medical devices EIT has managed to position itself successfully in the American market. Since launching its product in the USA, the company has increased its order volume tremendously.
|
|
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2014
Business purpose: Development and marketing of 3D printed fusion implants and instruments for spinal surgery applications. External implant production based on selective laser melting (SLM 3D printing) and regional distribution cooperations.
Products: Cervical cage, lumbar cages as well as an innovation portfolio comprising minimal-invasive access, customizability and other spine innovation projects.
Location: Wurmlingen (2016, D), established in Tuttlingen (D) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
Tyromotion receives "Top of Styria" award |
|
|
| |
| |
 |
| |
| Alexander Kollreider (2nd from left) at the award ceremony (photo: Harry Schiffer) |
|
|
|
At this year's "Top of Styria" business gala, the Graz-based high-tech rehabilitation specialist Tyromotion received an award for "Innovation". Tyromotion is one of the market leaders for robotics and computer-based rehabilitation equipment.
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2007
Business purpose: Development and distribution of robot-assisted and computer-assisted therapeutic devices for the rehabilitation sector, primarily for stroke patients
Products: Amadeo finger-hand-therapy, Diego arm-rehabilitation, Myro interactive therapy, Pablo hand-arm-Rehabilitation, Tymo therapy board
Location: Graz (A)
|
|
| |
|
|
|
|
|
| |
| |
|
|
| |
Follow-up financing for Miracor Medical |
|
|
| |
| |
Existing and new investors provided Miracor Medical a two-digit million sum in a follow-up round of financing. The fresh capital will be used to further develop Miracor's treatment technology PiCSO.
|
|
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2008
Business purpose: development and distribution of a therapy that reduces damage to the heart muscle following an attack or congestive heart failure
Products: PiCSO Impulse System (consisting of an impulse catheter and impulse console, which automatically controls the impulse catheter)
Locations: Vienna (A) and Manchester (UK)
|
|
| |
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
Event announcement: "Challenges and financing options for medical technology companies" on February 27th, 2018 in Tuttlingen Hausen ob Verena |
|
|
| |
| |
Together with the medical technology industry initiative Medical Mountains, MBG Baden-Württemberg and SHS Gesellschaft für Beteiligungsmanagement have organized the event "Challenges and Financing Options for Medical Technology Companies". It will take place on February 27th, 2018 in Hausen ob Verena, Germany. The focus here will be on succession planning and funding opportunities for growing medical technology companies. In addition to this, experts will be presenting interesting case studies. We look forward to seeing you there!
|
|
| |
|
|
|
| |
| |
|
|
| |
SHS at the Forum Medtech Pharma in Nuernberg |
|
|
| |
| |
At the Forum MedTech Pharma in November, managing director at SHS, Hubertus Leonhardt, provided insight into financing innovation projects. The workshops focused on current challenges for medical technology manufacturers.
|
|
|
|
|
.jpeg "ForumMedtechPharma") |
| |
| Dr. Matthias Schier, managing director of Forum Medtech Pharma (center) with the guest speakers |
|
|
|
|
| |
| |
|
|
| |
SHS at the CatCap Venture Lounge in Darmstadt |
|
|
| |
| |
.jpeg "CatCap") |
| |
| Cornelius Maas (2nd from left) at the Venture Lounge |
|
|
|
During the annual CatCap Venture Lounge, young companies once again had the opportunity to present themselves and their business cases to investors. SHS investment manager Cornelius Haas was a member of the jury.
|
|
|
|
|
|
| |
| |
|
|
|
|
|
|
|
| |
| |
Junior Investment Manager (m/f)
Read more »
|
|
| |
Managing Director / MBI candidate (m/f) for medical technology, succession solution
Read more »
|
|
| |
Internships for students
Read more »
|
|
| |
Master’s thesis at SHS
Read more »
|
|
| |
Master’s thesis at SHS – Digital Health
Read more »
|
|
|
| |
| |
|
|
| |
Jobs at portfolio companies |
|
|
| |
| |
CFO (m/f) member of the management board
Read more »
|
|
| |
Senior Development Engineer (m/f) for Medical Technology
Read more »
|
|
| |
CEO (m/f) Focus: research and development, clinical affairs and/or regulatory in medical technology
Read more »
|
|
| |
Vice President of Marketing & Sales US (m/f)
Read more »
|
|
| |
Senior Production Manager (m/f) 100%
Read more »
|
|
| |
COO (m/f) Subsidiary Rosenheim
Read more »
|
|
| |
Marketing Manager / Graphic Designer (m/f)
Read more »
|
|
|
| |
| |
|
|
|
|
|
|
|
| |
| |
Kleine Zeitung, 4 December 2017: "Großer Schritt für den Grazer Reha-Experten" (A big step for Graz-based rehabilitation experts) |
|
| |
The SHS portfolio company Tyromotion has developed "Omego", a new product for treating the lower extremities. It is particularly focused on improving the walking ability of stroke and paralysis patients. Together with SHS, Tyromotion intends to continue development of its product portfolio and market presence. |
|
| |
Read more » |
|
|
| |
| |
Laborpraxis, 8 December 2017: "Multiple Sklerose: Wie NMR und Machine Learning die Diagnostik verbessern können" (Multiple sclerosis: how NMR and machin learning can improve diagnostics) |
|
| |
The journal Laborpraxis examined the collaboration between the SHS portfolio company numares AG and Oxford University. The company and the university are working together on an in-vitro test to improve the diagnosis and treatment of multiple sclerosis. Using nuclear magnetic resonance spectroscopy and machine learning tools, innovative diagnostic tests will be developed to identify metabolic relationships arising from MS. Among other things, Dr. Maximilian Zucker, head of development at numares AG, spoked about the use of artificial intelligence in the development of the test. |
|
| |
Read more » |
|
|
| |
| |
Technology Networks, 8 December 2017: "How Software Based Technologies Help Developing Precise and Effective in vitro Diagnostics" |
|
| |
In an exciting interview, Dr. Phillip Pagel, CMO of numares AG, spoke about the limitations of in-vitro diagnostics and how they can be overcome using software based technologies. He also discussed how numares is combining artificial intelligence and nuclear magnetic resonance spectroscopy to develop diagnostic tests. |
|
| |
Read more » |
|
|
| |
| |
|
|
| |
|
|
| |
Investment focus
|
|
| |
|
|
| |
| Sector: |
|
life sciences (medical technology, diagnostics, applied technologies, digital health, industrial biotechnology/pharmaceutical industry; no drug development) |
| Geographical Focus: |
|
Germany, Austria, Switzerland, Scandinavia, Benelux |
| Reasons for investment: |
|
growth capital, strengthening equity, MBO/MBI, change of shareholders/succession, M&A financing, spin-off |
| Company situation: |
|
growth/expansion, succession/company sale, internationalization; operating profit may be negative for growth, or for technology-related reasons |
| Transaction value and investment size: |
|
transaction value: up to € 100m; investment amount:
€ 2-30m, with a co-investor from the SHS-network up to € 60m |
| Investment types: |
|
majorities or minorities, equity & financial instruments similar to equity |
|
|
| |
|
|
|
|
|
| |
|
|
| |
|
The SHS Newsletter is
published by:
SHS Gesellschaft für Beteiligungsmanagement mbH
|
|
Bismarckstrasse 12
72072 Tuebingen
Germany
www.shs-capital.eu
|
|
Tel +49 7071 9169-0
Fax +49 7071 9169-190
To unsubscribe the newsletter, please click here.
|
|
|
| |
|
|
| |
Editorial team: SHS Gesellschaft für Beteiligungsmanagement mbH, Ira Wülfing Kommunikation GmbH | Design and technical realisation: UNIBRAND GmbH
To open this newsletter as a PDF file please click here.
|
|
| |
|
|
|
|
| |
|
.jpeg "EIT")
.jpeg "MIR Logo")